Abstract. Diffuse cutaneous leishmaniasis (DCL) is characterized by disseminated lesions and the absence of a specific cellular immune response. Here, the immunochemotherapy outcome of a patient with DCL from Amazonian Brazil infected with Leishmania ( Leishmania ) amazonensis is presented. After several unsuccessful chemotherapy treatment regimens and many relapses, a monthly immunotherapy scheme of L. amazonensis PH8 plus L. ( Viannia ) braziliensis M2903 monovalent vaccines associated with Bacillus Calmette-Guerin (BCG) was established, one round of which also included an M2903 vaccine associated with intermittent antimonial treatment. Temporary healing of all lesions was achieved, although Leishmania skin tests were negative and interferon γ was not detected in mononuclear cell cultures stimulated with Leishmania antigens. The frequencies of CD16 + CD56
INTRODUCTION
Diffuse cutaneous leishmaniasis (DCL) is a rare disease characterized by the presence of non-ulcerative disseminated nodules that may cover several parts of the patient's body. In the New World, it is caused by Leishmania complex species such as Leishmania ( Leishmania ) amazonensis , which is the causal agent in Brazil. Histopathologic analysis of the dermis of infected individuals shows a severe infiltration of vacuolated macrophages containing abundant parasites. A humoral immune response is detected in patients, but specific cell immunity is absent. [1] [2] [3] There is no effective treatment for DCL, and relapses frequently occur even when immunotherapy is used in an attempt to induce a specific cellular immune response. [4] [5] [6] A vaccine containing killed Leishmania promastigotes and Bacillus Calmette-Guerin (BCG) was described to improve healing and the immune response against Leishmania when used alone or in combination with chemotherapy to treat DCL patients. 7, 8 The BCG leads to the activation of innate immune system cells such as macrophages and natural killer (NK) cells. 9 BCG increases NO, reactive oxygen intermediates, and tumor necrosis factor (TNF) production, all of which are important molecules for the leishmanicidal activity of macrophages. [10] [11] [12] Besides TNF, other cytokines are released from BCG-activated monocytes/macrophages, and they are potent NK cell activators. 9 BCG also directly activates NK cells, which are able to kill tumor cells, Leishmaniainfected macrophages, and even free parasites, 9, 13 as well as being able to produce cytokines to activate monocytes/macrophages. 14 Interferon γ (IFNγ), produced by NK cells, and TNF work synergistically to induce macrophage leishmanicidal activity and to control Leishmania infection. 10, 15 In this study, we report a transitory remission of all lesions in a patient with DCL treated with L. 
MATERIALS AND METHODS
Patient description. MAB is a 22-year-old man, from Amazonian Brazil, who presented with cutaneous lesions at age 4; during the following 14 years, he received different schedules of treatment with pentavalent antimonial and pentamidine and showed periods of improvement and relapse. In 2003, he was assisted at the Tropical Medicine Hospital (Anuar Auad Hospital) in Goiânia, Goiás, Brazil. A clinical exam showed disseminated cutaneous lesions on the body, including papules, nodules (both infiltrating and vegetative), and ulcerative lesions.
Isolation of parasites, histopathologic examinations, and species identification. Informed consent was signed by the patient, and the protocols for human and animal procedures were approved by a local ethics committee (Ethics Committee in Animal and Human Research of the Clinical Hospital of Federal University of Goiás). Biopsy fragments of lesions were macerated and injected into the footpad of IFNγ-deficient C57Bl/6 mice for in vivo parasite isolation or cultured in Grace's insect medium (Gibco BRL, Grand Island, NY ) for in vitro isolation. Paraffin-embedded 3-μm tissue sections were stained using hematoxylin-eosin (H&E) or submitted to immunohistochemistry (IHC) with rabbit polyclonal antibodies anti-Leishmania spp. (kindly supplied by Dr. Luis Antônio Freitas, Bahia, Brazil). After incubation with these antibodies, sections were treated with streptoavidin-biotinperoxidase (kit-LSAB-plus; Dako, Glostrup, Denmark ) and counterstained with Mayer hematoxylin. DNA was extracted from promastigotes, 16 and small subunit ribosomal DNA (SSU rDNA) sequence amplification was performed according to Uliana and others, using primers S1/S4. 17 The nucleotide sequence of the resulting fragment of 520 bp was obtained directly by automatic sequencing using an ABI Big-Dye kit. The vaccine preparations used in this study were produced using well-defined World Health Organization reference strains and a methodology described in detail by Mendonça and others. 19 The vaccines (600 μg) plus BCG (400 μg; the dose of BCG was decreased 100 μg each month until 100 μg, which was used until relapses, when the dose was increased again to 400 μg) were inoculated intradermally (ID) in three different places (300 μL each injection). The BCG was administered until obtaining of a positive protein purified derivative (PPD) reaction (30 months of use), and after that, he received the vaccines alone. During the immune stimulation (vaccine + BCG), he also underwent chemotherapy regimens of Glucantime, liposomal amphotericin B, and azithromycin (Azidromic; Royton, São Paulo, SP, Brazil ). The patient also received an intermittent schedule of Glucantime plus M2903 vaccine. These procedures were based on Mayrink and others 20 and Toledo and others.
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Skin tests and indirect immunofluorescence reaction. The skin test was performed using antigen preparations from two different laboratories, both of which were a preparation of L. ( L. ) amazonensis (MHOM/BR/73/M2269) containing 40 μg/mL total nitrogen (ISEP, Curitiba, PR, Brazil and Federal University of Minas Gerais, Belo Horizonte, MG, Brazil). PPD (2 T.U./0.1 mL; Statens Serum Institut, Copenhagen, Denmark ) was used to test the in vivo immune response to BCG. The antigens (0.1 mL) were injected ID into the forearm, and after 72 hours, the reaction was considered positive when induration at the site of injection was ≥ 5 mm. Peripheral blood was collected, and serum was submitted to an indirect immunofluorescence (IIF) reaction using promastigote forms of L. Ouro Preto, MG, Brazil ). All procedures were performed according to Toledo and others. 21 For immunophenotyping assay of peripheral blood leukocytes, 100-μL aliquots of whole peripheral blood collected in EDTA were added to 5 μL of monoclonal antibodies (mAbs) specific for human NK and monocyte cell surface markers, including anti-CD3-FITC and TC (Clone HIT3a), CD14-PE (TÜK4), CD16-FITC (Clone 3G8), and CD56-PE (Clone MEM-188). Isotypic controls included mouse IgG1 (Clone G18-145) and IgG2 (Clone G18-145) labeled with FITC, PE, or TC. The mAbs were purchased from Dako (Carpinteria, CA ), Becton Dickinson (Mountain View, CA ), or Caltag (Burlingame, CA ). After erythrocyte lysis, cytofluorimetric data acquisition was performed in a Becton Dickinson FACScalibur instrument. CELLQUEST software provided by the manufacturer was used for data acquisition and analysis. + monocytes was performed according to Ziegler-Heitbrok and others. 24 Paraffin-embedded 3-μm tissue sections were treated with mAb against the CD56 antigen (123C3.D5, mouse IgG1; 1/100; BioSB, Santa Barbara, CA ). Afterward, the sections were incubated with streptoavidin-biotin-peroxidase (Kit-LSAB-plus; Dako Cytomation, Glostrup, Denmark ) and DAB (3,3-diaminobenzidine tetrahydrochloride; Sigma). For counterstaining, Mayer hematoxylin was used. Table 1 . Although there was some clinical improvement, most notably the size of the lesions, not all lesions healed completely, and relapses occurred soon after each treatment (~1 month). In these 14 months of chemotherapy, the patient received medication during almost 9 of the months.
RESULTS

Laboratory diagnosis, parasite isolation
In September 2004, he started to receive the monovalent PH8 and M2903 vaccines plus BCG monthly. After 10 months of immunochemotherapy, the best clinical results throughout all therapeutic attempts were observed. Although some relapses occurred during the treatment, the interval between these relapses was increased (from 2 to 9 months), and lesions were less severe each time, with reduced size and infiltration. After 30 months of immunochemotherapy, the PPD became positive. From that point, the patient received monovalent PH8 and M2903 vaccines without BCG. By May 2007, 32 months after the beginning of the immunochemotherapy, all lesions had healed. During this 30-month period of immunotherapy, the patient received medication during only 9 months ( Table 1 ) . Figure 2 presents the clinical evolution of the patient before and after treatment, whereas Figure 3A and B depicts tissue lesions showing an intense mononuclear cell infiltration in the dermis, with the appearance of macrophage granuloma. Figure 3C and D shows H&E and IHC images of vacuolated macrophages that were heavily parasitized. Figure 3E and F shows aspects of a healing lesion with intense collagen deposits and mononuclear cell infiltration.
During treatment, skin tests were performed, and all of them were negative for L. ( L. ) amazonensis , except for one that presented a reaction of 5 mm in February 2005. At the time of clinical cure, cytokines were not detected in the supernatants of peripheral blood mononuclear cell cultures assayed with Leishmania antigens. Nonspecific stimulation with PHA, however, induced IFNγ (2 ng/mL) and TNF (427 pg/mL). In contrast, the humoral immune response was detected during and after healing, with the levels of specific IgG around a titer of 160.
Peripheral + NK cell frequencies (~8× and ~2−, respectively; Figure 4A ) in peripheral blood. The increase of NK cells was especially marked in the CD16 + CD56
dim NK cell subset, as observed in Figure 4B . In addition, whereas CD56 + lymphocytes were scarcely found in active lesions ( Figure 4C ), these cells were found in a high number in healing lesions ( Figure 4D ).
DISCUSSION
In this study, we described a patient with DCL treated with immunochemotherapy using Leishmania vaccines plus BCG for an extended period. The patient received several treatments during his 18 years of disease, and the treatment described here was the first that completely resolved, albeit temporarily, all his lesions. In addition, when the lesions reappeared during immunochemotherapy, each time they became less severe, leading to a significant improvement in the quality of life after many years of living with the disease. The side effects of immunotherapy were less severe than those of the chemotherapy, being restricted to inflammatory reactions at the injection site of vaccine plus BCG. Because the immunotherapy led to a reduction in the frequency of remissions and an increase in the intervals between them, less chemotherapy was necessary to control the lesions, which decreased the overall 
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Immunochemotherapy: the patient received medication during almost 9 months of this 30-month period, increasing the intervals between relapses to > 2 months (from 2 to 9 months). This schedule reduced costs and suffering. side effects of the therapy and reduced patient suffering. Furthermore, the cost of the immunotherapy is low, and its use reduced the cost of chemotherapy. Leishmania ( L. ) amazonensis PH8 and L. ( V. ) braziliensis M2903 monovalent vaccines were selected to induce both a species-specific immune response and also a cross-protective immune response. BCG has been used in an attempt to create a milieu favoring the development of a cellular immune response, especially by activating monocytes, macrophages, dendritic cells, and NK cells to cooperate with antigen-specific T lymphocytes. 9, 15, 25, 26 After several months of immunotherapy, despite the apparent clinical cure of all lesions, a Leishmaniaspecific cellular immune response was not detected. Our data are similar to previous results showing that patients with DCL not only present relapses, but frequently, they do not develop a specific cell immune response. 4, 5 In contrast, Convit and others 8 showed that treatment of patients of DCL with a vaccine containing promastigotes of L. ( V. ) braziliensis and BCG leads to both a clinical cure and a positive Leishmania skin test, suggesting that it is possible to achieve an effective immunomodulation to improve specific cellular immune response in some patients with DCL.
We studied possible alterations in the blood frequency of monocytes and NK cells that can be directly activated by BCG and also by Leishmania promastigotes. 9, 14, 27, 28 When all lesions healed, we found an increase in CD16 + CD56
+ NK cell frequency (~2×). The subpopulation of CD56 dim NK cells was preferentially increased. This subpopulation represents the majority of NK cells in peripheral blood (~90% of NK cells), contains high cytotoxic activity, and migrates to inflammatory sites where these cells can interact with different cells of the immune system. 29, 30 In fact, we found CD56 + lymphocytes in healing lesions, suggesting an infiltration of CD56 + NK cells at these sites. Although there is not an unequivocal means to identify NK cells in tissue sections, the presence of CD56 + lymphocytes in patient lesions is suggestive of NK cells. Thus, we speculate that in infected sites, activated NK cells can lyse infected macrophages and parasites, and in addition, they can release IFNγ and TNF to activate macrophages for parasite elimination. Corroborating our data, it has been shown that IFNγ-producing NK cells increased in the DCL lesions and parasites decreased concomitantly after immunochemotherapy with pentamidine, allopurinol, and IFNγ. 4 We found a significant increase in the frequency of blood CD14 + CD16
+ monocytes, which are considered proinflammatory cells because they produce TNF, but not the anti-inflammatory cytokine interleukin-10. 24 Whereas TNF is important to activate macrophage leishmanicidal activity, a decrease in IL-10 production is associated with transient cure in DCL. 31 It has been suggested that a high frequency of CD14 + CD16 + monocytes at diagnosis of localized cutaneous form of leishmaniasis could be associated with disease severity. 32 Nevertheless, as seen in this case, CD14 + CD16
+ monocytes can release TNF to activate NK cells 33 ; thus, these cells can help establish a distinct outcome in patients with DCL.
To our knowledge, this is the first description of NK cell and monocyte subset alterations in a patients with DCL treated with Leishmania vaccines plus BCG and chemotherapy. Our results highlight the relevance of the activation of the innate immune system for Leishmania control, especially when the acquired immune system is not effectively activated. 
